References

Marian S. McDonagh; Jesse Wagner; Azrah Y. Ahmed; Rongwei Fu; Benjamin Morasco; Devan Kansagara; Roger Chou

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

McDonagh MS, Wagner J, Ahmed AY, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Oct. (Comparative Effectiveness Review, No. 250.)

Cover of Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain [Internet].

Show details

Contents

< Prev Next >

References

1.: Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain–United States, 2016. Jama. 2016 Apr 19;315(15):1624–45. doi: 10.1001/jama.2016.1464. PMID: 26977696. [PMC free article: PMC6390846] [PubMed: 26977696] [CrossRef]
2.: Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016 Mar 18;65(1):1–49. doi: 10.15585/mmwr.rr6501e1. PMID: 26987082. [PubMed: 26987082] [CrossRef]
3.: Dahlhamer J LJ, Zelaya, C, et al. . Prevalence of chronic pain and high-impact chronic pain among adults — United States, 2016. MMWR Morb Mortal Wkly Rep 2018. doi: 10.15585/mmwr.mm6736a2. [PMC free article: PMC6146950] [PubMed: 30212442] [CrossRef]
4.: Institute of Medicine Committee on Advancing Pain Research. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: National Academies Press; National Academy of Sciences; 2011. [PubMed: 22553896]
5.: Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain. 2008 Jul-Aug;24(6):469–78. doi: 10.1097/AJP.0b013e31816b2f26. PMID: 18574357. [PubMed: 18574357] [CrossRef]
6.: Eriksen J, Sjogren P, Bruera E, et al. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006 Nov;125(1-2):172–9. doi: 10.1016/j.pain.2006.06.009. PMID: 16842922. [PubMed: 16842922] [CrossRef]
7.: U.S. Centers for Disease Control and Prevention. Annual Surveillance Report of Drug-Related Risks and Outcomes-United States, 2017. Special Surveillance Special Report 1. Atlanta, GA: 2018. https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf.
8.: Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487–92. PMID: 22048730. [PubMed: 22048730]
9.: Drug Abuse Warning Network. The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; Center for Behavioral Health Statistics and Quality; 2012. https://www.samhsa.gov/data/sites/default/files/DAWN096/DAWN096/SR096EDHighlights2010.htm. [PubMed: 27631059]
10.: U.S. Department of Health and Human Services. HHS Acting Secretary Declares Public Health Emergency to Address National Opioid Crisis. HHS Press Office; 2017. https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html. Accessed Jul 30 2020.
11.: Chou R, Hartung D, Turner J, et al. Opioid Treatments for Chronic Pain. Comparative Effectiveness Review No. 229. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I.) AHRQ Publication No. 20-EHC011. Rockville, MD: Agency for Healthcare Research and Quality; April 2020. PMID: 32338848. [PubMed: 32338848]
12.: McDonagh MS, Selph SS, Buckley DI, et al. Nonopioid Pharmacologic Treatments for Chronic Pain. Comparative Effectiveness Review No. 228. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I.) AHRQ Publication No. 20-EHC010. Rockville, MD: Agency for Healthcare Research and Quality; April 2020. PMID: 32338847. [PubMed: 32338847]
13.: Skelly AC, Chou R, Dettori JR, et al. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update. Comparative Effectiveness Review No. 227. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I.) AHRQ Publication No. 20-EHC009. Rockville, MD: Agency for Healthcare Research and Quality; April 2020. PMID: 32338846. [PubMed: 32338846]
14.: Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018 Oct;159(10):1932–54. doi: 10.1097/j.pain.0000000000001293. PMID: 29847469. [PubMed: 29847469] [CrossRef]
15.: Elikkottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag. 2009 Nov-Dec;5(6):341–57. PMID: 20073408. [PMC free article: PMC3728280] [PubMed: 20073408]
16.: Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. Jama. 2015 Jun 23-30;313(24):2456–73. doi: 10.1001/jama.2015.6358. PMID: 26103030. [PubMed: 26103030] [CrossRef]
17.: Vučković S, Srebro D, Vujović KS, et al. Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. 2018;9:1259-. doi: 10.3389/fphar.2018.01259. PMID: 30542280. [PMC free article: PMC6277878] [PubMed: 30542280] [CrossRef]
18.: Morales P, Hurst DP, Reggio PH. Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod. 2017;103:103–31. doi: 10.1007/978-3-319-45541-9_4. PMID: 28120232. [PMC free article: PMC5345356] [PubMed: 28120232] [CrossRef]
19.: Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. J Pain. 2016 06;17(6):739–44. doi: 10.1016/j.jpain.2016.03.002. PMID: 27001005. [PubMed: 27001005] [CrossRef]
20.: Boehnke KF, Scott JR, Litinas E, et al. Pills to Pot: Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain. J Pain. 2019 07;20(7):830–41. doi: 10.1016/j.jpain.2019.01.010. PMID: 30690169. [PubMed: 30690169] [CrossRef]
21.: Piper BJ, DeKeuster RM, Beals ML, et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017 May;31(5):569–75. doi: 10.1177/0269881117699616. PMID: 28372506. [PubMed: 28372506] [CrossRef]
22.: Corroon JM, Jr., Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs - a cross-sectional study. J Pain Res. 2017;10:989–98. doi: 10.2147/jpr.S134330. PMID: 28496355. [PMC free article: PMC5422566] [PubMed: 28496355] [CrossRef]
23.: Swogger MT, Walsh Z. Kratom use and mental health: A systematic review. Drug Alcohol Depend. 2018 Feb 1;183:134–40. doi: 10.1016/j.drugalcdep.2017.10.012. PMID: 29248691. [PubMed: 29248691] [CrossRef]
24.: White CM. Pharmacologic and clinical assessment of kratom: An update. Am J Health-Syst Pharm. 2019 11 13;76(23):1915–25. doi: 10.1093/ajhp/zxz221. PMID: 31626272. [PubMed: 31626272] [CrossRef]
25.: Risks of Adolescent Marijuana Use. U.S. Department of Health & Human Services; Office of Population Affairs. https://www.hhs.gov/ash/oah/adolescent-development/substance-use/marijuana/risks/index.html. Accessed May 25, 2020.
26.: Swetlitz I. HHS recommended that the DEA make kratom a Schedule I drug, like LSD or heroin. PBS; 2018. https://www.pbs.org/newshour/nation/hhs-recommended-that-the-dea-make-kratom-a-schedule-i-drug-like-lsd-or-heroin. Accessed Jul 14 2021.
27.: Boehnke KF, Gangopadhyay S, Clauw DJ, et al. Qualifying Conditions Of Medical Cannabis License Holders In The United States. Health Aff (Millwood). 2019 02;38(2):295–302. doi: 10.1377/hlthaff.2018.05266. PMID: 30715980. [PMC free article: PMC6398594] [PubMed: 30715980] [CrossRef]
28.: Jaeger K. Congressional Committee Slams Schedule I And Calls For Marijuana And Kratom Research. Marijuana Moment; 2019. https://www.marijuanamoment.net/congressional-committee-slams-schedule-i-and-calls-for-marijuana-and-kratom-research/. Accessed Jul 14 2021.
29.: NIDA. Hearing on Cannabis Policies for the New Decade. 2020. https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2020/hearing-on-cannabis-policies-for-the-new-decade. Accessed Jul 14 2021.
30.: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2017. https://effectivehealthcare.ahrq.gov/topics/cer-methods-guide/overview. Accessed June 1, 2019. [PubMed: 21433403]
31.: Chou R, Deyo R, Friedly J, et al. Noninvasive Treatments for Low Back Pain: Agency for Healthcare Research and Quality (US), Rockville (MD); 2016. [PubMed: 26985522]
32.: Skelly AC, Chou R, Dettori JR, et al. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review: Agency for Healthcare Research and Quality (US), Rockville (MD); 2018. [PubMed: 30179389]
33.: Morton SC, Murad MH, O’Connor E, et al. Quantitative Synthesis—An Update: Agency for Healthcare Research and Quality (US), Rockville (MD); 2008. [PubMed: 30125065]
34.: Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557–60. doi: 10.1136/bmj.327.7414.557. PMID: 12958120. [PMC free article: PMC192859] [PubMed: 12958120] [CrossRef]
35.: Hardy RJ, Thompson SG. A likelihood approach to meta-analysis with random effects. Stat Med. 1996 Mar 30;15(6):619–29. doi: 10.1002/(sici)1097-0258(19960330)15:6<619::Aid-sim188>3.0.Co;2-a. PMID: 8731004. [PubMed: 8731004] [CrossRef]
36.: Berkman ND, Lohr KN, Ansari MT, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol. 2015 Nov;68(11):1312–24. doi: 10.1016/j.jclinepi.2014.11.023. PMID: 25721570. [PubMed: 25721570] [CrossRef]
37.: Gerrity M, Fiordalisi C, Pillay J, et al. Roadmap for Narratively Describing Effects of Interventions in Systematic Reviews. AHRQ Methods for Effective Health Care. 2020 PMID: 33180401. [PubMed: 33180401]
38.: Murad MH, Fiordalisi C, Pillay J, et al. Making Narrative Statements to Describe Treatment Effects. J Gen Intern Med. 2021 Jan;36(1):196–9. doi: 10.1007/s11606-020-06330-y. PMID: 33111244. [PMC free article: PMC7858734] [PubMed: 33111244] [CrossRef]
39.: Gerrity M, Fiordalisi C, Pillay J, et al. AHRQ Methods for Effective Health Care. Roadmap for Narratively Describing Effects of Interventions in Systematic Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020. [PubMed: 33180401]
40.: Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45(1):50–2. PMID: 16282192. [PubMed: 16282192]
41.: Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013 Apr;260(4):984–97. doi: 10.1007/s00415-012-6739-4. PMID: 23180178. [PubMed: 23180178] [CrossRef]
42.: Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014 Jan;47(1):166–73. doi: 10.1016/j.jpainsymman.2013.02.018. PMID: 23742737. [PubMed: 23742737] [CrossRef]
43.: Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007 Dec 15;133(1-3):210–20. PMID: 17997224. [PubMed: 17997224]
44.: Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005 Sep 27;65(6):812–9. PMID: 16186518. [PubMed: 16186518]
45.: Selvarajah D, Gandhi R, Emery CJ, et al. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010 Jan;33(1):128–30. doi: 10.2337/dc09-1029. PMID: 19808912. [PMC free article: PMC2797957] [PubMed: 19808912] [CrossRef]
46.: Serpell M, Ratcliffe S, Hovorka J, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014 Aug;18(7):999–1012. doi: 10.1002/j.1532-2149.2013.00445.x. PMID: 24420962. [PubMed: 24420962] [CrossRef]
47.: Chaves C, Bittencourt PCT, Pelegrini A. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Pain Med. 2020;21(10):2212–8. doi: 10.1093/pm/pnaa303. PMID: 33118602. [PMC free article: PMC7593796] [PubMed: 33118602] [CrossRef]
48.: Zajicek JP, Hobart JC, Slade A, et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125–32. doi: 10.1136/jnnp-2012-302468. PMID: 22791906. [PubMed: 22791906] [CrossRef]
49.: de Vries M, van Rijckevorsel DCM, Vissers KCP, et al. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1079–86.e4. doi: 10.1016/j.cgh.2016.09.147. PMID: 27720917. [PubMed: 27720917] [CrossRef]
50.: Frank B, Serpell MG, Hughes J, et al. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 2008 Jan 26;336(7637):199–201. doi: 10.1136/bmj.39429.619653.80. PMID: 18182416. [PMC free article: PMC2213874] [PubMed: 18182416] [CrossRef]
51.: Pini LA, Guerzoni S, Cainazzo MM, et al. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain. 2012 Nov;13(8):677–84. doi: 10.1007/s10194-012-0490-1. PMID: 23070400. [PMC free article: PMC3484259] [PubMed: 23070400] [CrossRef]
52.: Rintala DH, Fiess RN, Tan G, et al. Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil. 2010 Oct;89(10):840–8. doi: 10.1097/PHM.0b013e3181f1c4ec. PMID: 20855984. [PubMed: 20855984] [CrossRef]
53.: Schimrigk S, Marziniak M, Neubauer C, et al. Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients. Eur Neurol. 2017;78(5-6):320–9. doi: 10.1159/000481089. PMID: 29073592. [PMC free article: PMC5804828] [PubMed: 29073592] [CrossRef]
54.: Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008 Feb;9(2):164–73. PMID: 17974490. [PubMed: 17974490]
55.: Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012 Oct;153(10):2073–82. doi: 10.1016/j.pain.2012.06.024. PMID: 22921260. [PubMed: 22921260] [CrossRef]
56.: Turcotte D, Doupe M, Torabi M, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med. 2015 Jan;16(1):149–59. doi: 10.1111/pme.12569. PMID: 25288189. [PubMed: 25288189] [CrossRef]
57.: Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol. 2006 Oct;253(10):1337–41. PMID: 16988792. [PubMed: 16988792]
58.: Xu DH, Cullen BD, Tang M, et al. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2020;21(5):390–402. doi: 10.2174/1389201020666191202111534. PMID: 31793418. [PubMed: 31793418] [CrossRef]
59.: Eibach L, Scheffel S, Cardebring M, et al. Cannabidivarin for HIV-Associated Neuropathic Pain: A Randomized, Blinded, Controlled Clinical Trial. Clin Pharmacol Ther. 2020 Aug 08;08:08. doi: 10.1002/cpt.2016. PMID: 32770831. [PubMed: 32770831] [CrossRef]
60.: Bestard JA, Toth CC. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 2011 Jul-Aug;11(4):353–68. doi: 10.1111/j.1533-2500.2010.00427.x. PMID: 21087411. [PubMed: 21087411] [CrossRef]
61.: Ware MA, Wang T, Shapiro S, et al. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain. 2015 Dec;16(12):1233–42. doi: 10.1016/j.jpain.2015.07.014. PMID: 26385201. [PubMed: 26385201] [CrossRef]
62.: Lee C, Lin M, Martins KJB, et al. Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada. BMC Public Health. 2021;21(1):843. doi: 10.1186/s12889-021-10867-w. PMID: 33933061. [PMC free article: PMC8088205] [PubMed: 33933061] [CrossRef]
63.: Vigil JM, Stith SS, Adams IM, et al. Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PLoS ONE. 2017;12(11):e0187795. doi: 10.1371/journal.pone.0187795. PMID: 29145417. [PMC free article: PMC5690609] [PubMed: 29145417] [CrossRef]
64.: Gruber SA, Smith RT, Dahlgren MK, et al. No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms. Experimental and clinical psychopharmacology. 2021doi: 10.1037/pha0000435. PMID: 33764103. [PubMed: 33764103] [CrossRef]
65.: Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018 Jul;3(7):e341–e50. doi: 10.1016/s2468-2667(18)30110-5. PMID: 29976328. [PMC free article: PMC6684473] [PubMed: 29976328] [CrossRef]
66.: Merlin JS, Long D, Becker WC, et al. Marijuana Use Is Not Associated With Changes in Opioid Prescriptions or Pain Severity Among People Living With HIV and Chronic Pain. J Acquir Immune Defic Syndr. 2019 06 01;81(2):231–7. doi: 10.1097/QAI.0000000000001998. PMID: 30865181. [PMC free article: PMC6522289] [PubMed: 30865181] [CrossRef]
67.: Kansagara D, O’Neil M, Nugent S, et al. Benefits and Harms of Cannabis in Chronic Pain or Post-traumatic Stress Disorder: A Systematic Review. Department of Veterans Affairs (US), Washington (DC); 2017. [PubMed: 29369568]
68.: Mucke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018 03 07;3:CD012182. doi: 10.1002/14651858.CD012182.pub2. PMID: 29513392. [PMC free article: PMC6494210] [PubMed: 29513392] [CrossRef]
69.: Nugent SM, Morasco BJ, O’Neil ME, et al. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review. Ann Intern Med. 2017 Sep 05;167(5):319–31. doi: 10.7326/M17-0155. PMID: 28806817. [PubMed: 28806817] [CrossRef]
70.: Okusanya BO, Asaolu IO, Ehiri JE, et al. Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review. Syst. 2020 Jul 28;9(1):167. doi: 10.1186/s13643-020-01425-3. PMID: 32723354. [PMC free article: PMC7388229] [PubMed: 32723354] [CrossRef]
71.: Longo R, Oudshoorn A, Befus D. Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials. Pain Manag Nurs. 2020doi: 10.1016/j.pmn.2020.11.006. PMID: 33353819. [PubMed: 33353819] [CrossRef]
72.: Wong SSC, Chan WS, Cheung CW. Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression. J Neuroimmune Pharmacol. 2020 Mar 14;14:14. doi: 10.1007/s11481-020-09905-y. PMID: 32172501. [PubMed: 32172501] [CrossRef]
73.: Kurlyandchik I, Tiralongo E, Schloss J. Safety and Efficacy of Medicinal Cannabis in the Treatment of Fibromyalgia: A Systematic Review. Journal of alternative and complementary medicine (New York, N.Y.). 2020doi: 10.1089/acm.2020.0331. PMID: 33337931. [PubMed: 33337931] [CrossRef]
74.: Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I. Value Health. 2009 Nov-Dec;12(8):1044–52. doi: 10.1111/j.1524-4733.2009.00600.x. PMID: 19793072. [PubMed: 19793072] [CrossRef]
75.: Furlan A, Chaparro LE, Irvin E, et al. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag. 2011 Sep-Oct;16(5):337–51. doi: 10.1155/2011/465281. PMID: 22059206. [PMC free article: PMC3206784] [PubMed: 22059206] [CrossRef]

Bookshelf ID: NBK575752

Contents

< Prev Next >

PubReader
Print View
Cite this Page
McDonagh MS, Wagner J, Ahmed AY, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Oct. (Comparative Effectiveness Review, No. 250.) References.
PDF version of this title (3.7M)